Zimmer Biomet (ZBH) Stock Price, News & Analysis

Company Overview

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices. In addition to implantable devices, Zimmer Biomet provides surgical power tools, instruments, biologics and bone graft materials, as well as preoperative planning, surgeon training and other clinical support services. The company has invested in digital tools and surgical technologies designed to support perioperative planning and improve procedural efficiency.

Zimmer Biomet traces its roots to long-established legacy businesses in the orthopaedics sector; Zimmer was founded in the early 20th century and Biomet began operations in the late 20th century, and the two companies combined in 2015 to form the current organization. Today the company serves markets around the world, commercializing products and supporting clinical customers across the Americas, Europe, Asia-Pacific and other regions through a network of sales, distribution and service operations.

Operating as a publicly traded company, Zimmer Biomet emphasizes research and development, regulatory compliance and strategic partnerships to advance its product pipeline and clinical offerings. Its business strategy centers on innovation in musculoskeletal care, expanding access to surgical solutions, and supporting clinicians with training and post-market services that aim to improve patient outcomes.

Key Stats

• Today's Range: $82.68 to $84.07
• 50-Day Range: $80.31 to $100.91
• 52-Week Range: $79.83 to $108.29
• Volume: 2.18 million shs
• Average Volume: 2.65 million shs
• Market Capitalization: $16.13 billion
• P/E Ratio: 21.66
• Dividend Yield: 1.15%
• Price Target: $102.80
• Consensus Rating: Hold

Zimmer Biomet Stock Analysis - MarketRank™

Zimmer Biomet scored higher than 81% of companies evaluated by MarketBeat, and ranked 97th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Zimmer Biomet has received a consensus rating of Hold. The company's average rating score is 2.26, and is based on 1 strong buy rating, 7 buy ratings, 12 hold ratings, and 3 sell ratings.

Upside Potential

Zimmer Biomet has a consensus price target of $102.80, representing about 23.3% upside from its current price of $83.38.

Amount of Analyst Coverage

Zimmer Biomet has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.79%

Earnings Growth

Earnings for Zimmer Biomet are expected to grow by 5.79% in the coming year, from $8.47 to $8.96 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zimmer Biomet is 21.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zimmer Biomet is 21.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.68.

Price to Earnings Growth Ratio

Zimmer Biomet has a PEG Ratio of 1.91. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zimmer Biomet has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.28% of the float of Zimmer Biomet has been sold short.

Short Interest Ratio / Days to Cover

Zimmer Biomet has a short interest ratio ("days to cover") of 5.07.

Change versus previous month

Short interest in Zimmer Biomet has recently increased by 0.85%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Zimmer Biomet pays a meaningful dividend of 1.16%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zimmer Biomet does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Zimmer Biomet is 24.94%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 10.71% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.80

News Sentiment

Zimmer Biomet has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Zimmer Biomet this week, compared to 7 articles on an average week.

Search Interest

Only 7 people have searched for ZBH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Zimmer Biomet to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zimmer Biomet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $250,849.00 in company stock.

Percentage Held by Insiders

1.28% of the stock of Zimmer Biomet is held by insiders.

Percentage Held by Institutions

88.89% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZBH Stock Analysis - Frequently Asked Questions

How have ZBH shares performed this year?

Zimmer Biomet's stock was trading at $89.94 on January 1st, 2026. Since then, ZBH shares have decreased by 7.3% and is now trading at $83.3760.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) released its earnings results on Tuesday, April, 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts' consensus estimates of $1.86 by $0.23. The business's revenue was up 9.3% on a year-over-year basis.
Read the conference call transcript.

Does Zimmer Biomet have any subsidiaries?

Zimmer Biomet subsidiaries include these companies: Respondwell, Clinical Graphics, CD Diagnostics, Medtech SAS, Compression Therapy Products, LDR Holding, Cayenne Medical, and others.

Who are Zimmer Biomet's major shareholders?

Top institutional investors of Zimmer Biomet include Dimensional Fund Advisors LP (1.15%), Bank of New York Mellon Corp (0.63%), Sound Shore Management Inc. CT (0.54%) and Swiss National Bank (0.30%). Insiders that own company stock include Chad F Phipps, Sang Yi, Lori Winkler, Robert Hagemann, Michael W Michelson and Sreelakshmi Kolli.
View institutional ownership trends.

How do I buy shares of Zimmer Biomet?

Shares of ZBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zimmer Biomet investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Record date for 4/30 Dividend: 3/31/2026
• Ex-Dividend for 4/30 Dividend: 3/31/2026
• Last Earnings: 4/28/2026
• Dividend Payable: 4/30/2026
• Today: 5/07/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ZBH
• Previous Symbol: NYSE:ZMH
• CIK: 1136869
• Web: www.zimmerbiomet.com
• Phone: (574) 267-6131
• Fax: 574-372-4988
• Employees: 17,000
• Year Founded: 1927

Price Target and Rating

• Average Price Target for Zimmer Biomet: $102.80
• High Price Target: $135.00
• Low Price Target: $83.00
• Potential Upside/Downside: +23.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.26
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.85
• Trailing P/E Ratio: 21.66
• Forward P/E Ratio: 9.84
• P/E Growth: 1.91
• Net Income: $705.20 million
• Net Margins: 9.05%
• Pretax Margin: 10.74%
• Return on Equity: 13.24%
• Return on Assets: 7.28%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.73
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $8.23 billion
• Price / Sales: 1.96
• Cash Flow: $13.83 per share
• Price / Cash Flow: 6.03
• Book Value: $65.55 per share
• Price / Book: 1.27

Miscellaneous

• Outstanding Shares: 193,460,000
• Free Float: 190,986,000
• Market Cap: $16.13 billion
• Optionable: Optionable
• Beta: 0.48